by Barry101 | Dec 8, 2022 | Press Release, Uncategorized
Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a prophylactic or early treatment against respiratory viral infections Data presented in poster presentation at the British...
by Barry101 | Dec 2, 2022 | Press Release, Uncategorized
OCALA, Fla., Dec. 02, 2022 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...
by Barry101 | Nov 15, 2022 | Press Release, Uncategorized
– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 OCALA, Fla., Nov. 15, 2022 — AIM ImmunoTech Inc....
by Barry101 | Nov 14, 2022 | Press Release, Uncategorized
– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic)...
by Barry101 | Nov 9, 2022 | Press Release, Uncategorized
Board Plans to Initiate Process to Add Two Additional Directors with Focus on Diverse Candidates who Possess Biotechnology Commercialization Experience Compensation Committee to Engage Nationally Recognized Independent Compensation Consultant to Evaluate Current...
